Palmar fibromatosis

2006 ◽  
pp. 682-682
Keyword(s):  
2003 ◽  
Vol 28 (3) ◽  
pp. 525-527 ◽  
Author(s):  
Keiichi Muramatsu ◽  
Koichiro Ihara ◽  
Shinya Kawai

1984 ◽  
Vol 405 (1) ◽  
pp. 41-53 ◽  
Author(s):  
H. Iwasaki ◽  
H. M�ller ◽  
H. J. Stutte ◽  
U. Brennscheidt

2018 ◽  
Vol 38 (2) ◽  
pp. 387-392 ◽  
Author(s):  
Gregory Morris ◽  
Jon A. Jacobson ◽  
Monica Kalume Brigido ◽  
Kara Gaetke-Udager ◽  
Corrie M. Yablon ◽  
...  

2016 ◽  
Vol 117 (1) ◽  
pp. 64-66
Author(s):  
Marios Papadakis ◽  
Andreas Manios ◽  
Constantinos Trompoukis

2021 ◽  
Vol 11 (1) ◽  
pp. 13-19
Author(s):  
Menna Allah M. SAAD ◽  
Amal M. ABD ELBAKY ◽  
Ashraf ABO ALFOTOOH ◽  
Karim I. SAAFAN

2018 ◽  
Vol 69 (3) ◽  
Author(s):  
Morio Hosoi ◽  
Gianni Belcaro ◽  
Andrea Ledda ◽  
Umberto Cornelli ◽  
Mark Dugall ◽  
...  

2005 ◽  
Vol 30 (6) ◽  
pp. 557-562 ◽  
Author(s):  
A. CORDOVA ◽  
M. TRIPOLI ◽  
B. CORRADINO ◽  
P. NAPOLI ◽  
F. MOSCHELLA

The so-called fibrogenic cytokines, able to induce the growth of fibroblasts and their differentiation into myofibroblasts and to stimulate their production of extracellular matrix, are involved in the genesis of Dupuytren’s contracture. Although many studies have been made of biomolecular aspects of palmar fibromatosis, practical applications from them are still far from imminent because of the real difficulty of blocking their action in vivo, even in a chronic, progressive lesion such as Dupuytren’s disease. Consequently, surgical excision of the palmar fascia still remains the treatment of choice.


Sign in / Sign up

Export Citation Format

Share Document